MedUni Vienna creates criteria for PET-based examinations of diffuse gliomas
Vienna (OTS) – Diffuse gliomas are malignant brain tumors and cannot be optimally examined using conventional imaging using MRI. Amino acid PET can better show the activity and spread of gliomas. An international research group (RANO Group), led by the MedUni Vienna and the LMU Munich, has now for the first time used international criteria for standardized imaging of gliomas Amino acid PET created. This groundbreaking work was published in the renowned journal “The Lancet Oncology”.
Under the joint leadership of oncologist Matthias Preusser from the Medical University of Vienna and nuclear medicine specialist Nathalie Albert from LMU Munich, the RANO group has developed new criteria for assessing the treatment response of diffuse gliomas. Tatjana-Traub Weidinger (University Clinic for Radiology and Nuclear Medicine) and Maximilian Mair (Clinical Department of Oncology, University Clinic for Internal Medicine I) from MedUni Vienna are also involved in the work.
Diffuse gliomas are malignant brain tumors that arise from glial cells in the brain. This type of tumor is usually aggressive and difficult to treat. The RANO Group has developed criteria that enable the evaluation of treatment success using positron emission tomography (PET). “These PET-based criteria, called PET RANO 1.0, open up new possibilities for the standardized assessment of diffuse gliomas,” says Matthias Preusser.
For the first time, comparable criteria for interpreting PET images
PET is an imaging technique that uses radioactively labeled substances to measure metabolic processes in the body. Amino acid PET is used to diagnose diffuse gliomas; its tracer is protein-based (amino acids) and accumulates in brain tumors. Nathalie Albert explains: “PET imaging with radioactively labeled amino acids has proven to be extremely valuable in neuro-oncology and enables reliable visualization of the activity and expansion of gliomas. Amino acid PET has been used for years, but has not yet been evaluated in a structured manner. In contrast Until now, there have been no criteria for interpreting these PET images for MRI-based diagnostics.”
“These new criteria will enable researchers and physicians to use PET in clinical studies and clinical routine,” adds Matthias Preusser, “they are based on expert consensus and create a basis for future studies and the comparison of treatments for improved Therapies.”
The Response Assessment in Neuro-Oncology (RANO) Working Group is an international, multidisciplinary consortium to develop new standardized response criteria for clinical trials in brain tumors. It is a group of experts from different disciplines who have been developing criteria that serve as standard references for assessing various clinically relevant aspects for more than ten years.
Publikation: The Lancet Oncology
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group.
Nathalie L. Albert, Norbert Galldiks, Benjamin M. Ellingson, Martin J. van den Bent, Susan M. Chang, Francesco Cicone, John de Groot, Eng-Siew Koh, Ian Law, Emilie Le Rhun, Maximilian J. Mair, Giuseppe Minniti, Roberta Rudà, Andrew M. Scott, Susan C. Short, Marion Smits, Bogdana Suchorska, Nelleke Tolboom, Tatjana Traub-Weidinger, Joerg-Christian Tonn, Antoine Verger, Michael Weller, Patrick Y. Wen, Matthias Preusser
https://doi.org/10.1016/S1470-2045(23)00525-9
Questions & Contact:
medical university Vienna
Mag. Johannes Angerer
Head of Communications and Public Relations
+431 40160-11501, +43 664 80016 11501
johannes.angerer@meduniwien.ac.at
http://www.meduniwien.ac.at